Review on Recent Development in Opioid Abuse-Deterrent Formulation Technologies and Regulatory Expectation
Pravinkumar Darji1*
, Jayendrakumar Patel1, Binit Patel2 , Shalin Parikh3 , Praneeth Ivan Joel Fnu1 and Seshadri Nalla41Exemplify Biopharma Inc., Cranbury, New Jersey, USA.
2Hovione, East Windsor, New Jersey, USA.
3Shree SK Patel College of Pharmaceutical Education and Research, Ganpat University, Mehsana, Gujarat, India.
4Lamar University, S M king Jr PKWY, Beaumont, Texas, USA.
Corresponding Author E-mail:palo378@gmail.com
Abstract: Chronic pain occurs as a result of several diseases and ailments. The problem of improper utilization of vital opioid medication has been a topic of substantial discourse during the last two decades, in conjunction with its application for the extended-term control of persistent pain. Abuse-deterrent formulations play a crucial role in comprehensive methods to manage the risks associated with opioids. These formulations diminish the allure and narcotic properties of opioids by restricting their capacity to be assimilated by the body. This diminishes the appeal and incentives for misusing altered opioid prescriptions, and also poses challenges in extracting the opioid substance for utilization in alternative manners. This article examines various regulatory measures, projected prerequisites for the licensing of abuse-deterrent formulations, and current activities aimed at producing opioid abuse-deterrent formulations as potential remedies to combat the opioid abuse pandemic. Considering the seriousness of the global opioid problem, it is crucial for various regulatory entities to come together to safeguard society from the opioid pandemic. This involves implementing a thorough policy on prescribing opioid medications to patients, conducting evaluations to determine the likelihood of addiction, and increasing efforts to approve only opioid drugs that are specifically tailored to prevent abuse.
Keywords: Abuse; Abuse Deterrent Technology; Opioid; Overdose; Regulatory Back to TOC